Studie zur Lslichkeit von Cannabis-Wirkstoffen - PharmaFood
| B1NT34 Stock | BRL 44.46 0.07 0.16% |
About 53% of BIONTECH's investor base is interested to short. The analysis of current outlook of investing in BIONTECH SE DRN suggests that many traders are impartial regarding BIONTECH's prospects. The current market sentiment, together with BIONTECH's historical and current headlines, can help investors time the market. In addition, many technical investors use BIONTECH SE DRN stock news signals to limit their universe of possible portfolio assets.
BIONTECH |
Studie zur Lslichkeit von Cannabis-Wirkstoffen PharmaFood
Read at news.google.com
 |
BIONTECH Fundamental Analysis
We analyze BIONTECH's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BIONTECH using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BIONTECH based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
BIONTECH is rated second in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
BIONTECH SE DRN Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BIONTECH stock to make a market-neutral strategy. Peer analysis of BIONTECH could also be used in its relative valuation, which is a method of valuing BIONTECH by comparing valuation metrics with similar companies.
Peers
BIONTECH Related Equities
| M1RN34 | Moderna | 3.69 | ||||
| BIOM3 | Biomm SA | 1.50 | ||||
| VRTX34 | Vertex Pharmaceuticals | 1.25 | ||||
| B1GN34 | BeiGene | 0.53 | ||||
| A1SN34 | Ascendis Pharma | 0.09 | ||||
| T1CH34 | Bio Techne | 0.00 | ||||
| B1NT34 | BIONTECH | 0.16 | ||||
| S1RP34 | Sarepta Therapeutics | 0.96 |
Complementary Tools for BIONTECH Stock analysis
When running BIONTECH's price analysis, check to measure BIONTECH's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BIONTECH is operating at the current time. Most of BIONTECH's value examination focuses on studying past and present price action to predict the probability of BIONTECH's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BIONTECH's price. Additionally, you may evaluate how the addition of BIONTECH to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |